TITLE

How does the Short Form 36 Health Questionnaire (SF-36) in Rheumatoid Arthritis (RA) Relate to RA Outcome Measures and SF-36 Population Values? A Cross-Sectional Study

AUTHOR(S)
Birrell, F. N.; Hassell, A. B.; Jones, P. W.; Dawes, P. T.
PUB. DATE
May 2000
SOURCE
Clinical Rheumatology;May2000, Vol. 19 Issue 3, p195
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: The aim of the study was to show that the SF-36 is a practical tool for use on outpatients with RA, to examine the relationship between the SF-36 and indices of outcome in RA, and to compare the results with population norms and other disease states. Eighty-six consecutive RA patients attending the Haywood Hospital in Stoke-on-Trent and starting or changing second-line therapy were enrolled. Disease outcome was assessed using the American College of Rheumatology core set and all subjects completed the SF-36 health questionnaire. The cohort had moderately active disease (median ESR 46) and appreciable disability (median HAQ 1.875). Impairment of health status was moderate to marked by the SF-36, with significant differences from population norms and chronic disease states such as low back pain. Good correlations were observed between HAQ and physical function (r>0.75, p<10–6) and HAQ and social function (r>0.61, p<10–6). In contrast, SF-36 scales for physical and emotional role showed no association with activity measures. We concluded that, SF-36 is a practical tool for use in patients with RA. HAQ is associated with its physical and social function scales. Other SF-36 scales, such as physical and emotional role, are not associated with activity core set measures; this suggests different information is involved. RA has a considerable impact on health status compared to other diseases.
ACCESSION #
15360733

 

Related Articles

  • Rheumatoid arthritis patients should be referred more swiftly. Dobson, Roger // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/9/2009, Vol. 338 Issue 7703, p1097 

    The article reports on a consensus statement on the treatment of rheumatoid arthritis in Great Britain that was published in a 2009 issue of "Rheumatology". The authors of the statement suggested that patients with rheumatoid arthritis should be referred to a specialist rheumatology clinic as...

  • Editorials: Sulphasalazine in rheumatoid arthritis: an old drug revived. Neumann, V. C.; Grindulis, K. A. // Journal of the Royal Society of Medicine;Mar1984, Vol. 77 Issue 3, p169 

    The article discusses the benefits of sulphasalazine in treating rheumatoid arthritis. Sulphasalazine is an old drug which is a compound of sulphapyridine and 5-aminosalicylic acid linked by an azo bond. The benefits of salicylates in rheumatoid arthritis have an excellent effect on the...

  • Disease-modifying drugs in rheumatoid arthritis. Warburton, Louise // Update;Jun2007, Vol. 74 Issue 6, p30 

    The article presents information on the therapeutic use of disease-modifying drugs (DMARDs) in rheumatoid arthritis (RA). It is reported that early diagnosis of RA enables early therapeutic intervention with DMARDs and a much better prognosis for the patient. Recently published guidelines of the...

  • Non-drug care for RA—is the era of evidence-based practice approaching? Vlieland, T. P. M. Vliet // Rheumatology;Sep2007, Vol. 46 Issue 9, p1397 

    Non-pharmacological treatment modalities are often recommended, prescribed and used in addition to drug treatment in patients with rheumatoid arthritis (RA). This article provides a review of the literature on their effectiveness.

  • Biomarker und personalisierte Medizin. Scherer, H.U.; Burmester, G.-R.; Häupl, T. // Zeitschrift für Rheumatologie;Feb2013, Vol. 72 Issue 1, p20 

    Biomarkers form the basis for patient stratification and the development of individualized treatment strategies. As the understanding of the pathophysiological processes underlying rheumatic diseases increases, novel biomarkers will become available and established markers can be used more...

  • When It Comes to TREATMENT, Early is Best. Mann, Denise; Siegfried, Donna Rae // Arthritis Today;May2005, Vol. 19 Issue 3, p38 

    Focuses on the benefits of early treatment for rheumatoid arthritis (RA). Drugs used for the treatment of RA; Risk of a patient for persistent disease; Achievement by people with early RA of clinical remission.

  • Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Péntek, Márta; Poór, Gyula; Wiland, Piotr; Olejárová, Martina; Brzosko, Marek; Codreanu, Catalin; Brodszky, Nóra; Gulácsi, László // European Journal of Health Economics;May2014 Supplement, Vol. 15, p35 

    Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug...

  • Using Biologic Agents in Pediatric Rheumatologic Diseases. Unsal, Erbil // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Mar2010, Vol. 9 Issue 1, p41 

    Juvenile Idiopathic Arthritis (JIA) is an "umbrella" term which is used to cover Juvenile Rheumatoid Arthritis (JRA) and Juvenile Chronic Arthritis (JCA). Biologic agents are needed when others like NSAIDs (Non-steroidal antiinflammatory agents), DMARDs (Disease modifying antirheumatic drugs)...

  • Early diagnosis of rheumatoid arthritis: an introduction to the newly designed Iran Criteria for Rheumatoid Arthritis. Salehi, Iraj; Khazaeli, Shabnam; Khak, Mohammad // Rheumatology International;Jan2013, Vol. 33 Issue 1, p45 

    More than 14 years of clinical practice in rheumatology led the author to discover the prognostic role of anti-citrullinated protein antibody (ACPA) as well as the erosions found by MRI, in detecting the RA patients resulting in establishing a new set of criteria by revising the 1987 ACR...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics